Association of gout medications and risk of cataract: a population-based case-control study
Association of gout medications and risk of cataract: a population-based case-control study
复制标题
DOI：
10.1093/qjmed/hcz167
复制
发表时间：
2019-11-01
影响因子：
13.3
通讯作者：
Wei, J. C-C
中科院分区：
文献类型：
--
作者：
Li, Y-J;Perng, W-T;Wei, J. C-C
背景：痛风药物使用与白内障发生之间的关系存在争议。此外，有限的临床研究已经评估了这种关系。目的：评估秋水仙碱，别嘌呤醇和苯溴马隆对痛风患者白内障风险的影响。设计：基于人群的巢式病例对照研究。方法：我们招募了7900名新诊断为白内障的患者，按年龄、性别和痛风确诊年份1：1匹配，将确诊痛风后3年的患者纳入研究组，33 475例未确诊白内障的患者纳入对照组。我们使用世界卫生组织的限定日剂量（DDD）作为评估秋水仙碱、别嘌呤醇和苯溴马隆暴露剂量的指标。结果：当秋水仙碱累积DDD ≥ 66.5时，白内障发生的危险性显著增加（OR=1.17，95%CI =1.01-1.36，P=0.041）。在年龄分层分析中，年龄>60岁的痛风患者发生白内障的风险（OR=1.27，95%CI =1.06-1.53，P=0.011）高于年龄> 60岁接受秋水仙碱治疗且累积DDD>66.5的患者。
Background: The relationship between gout medication use and cataract development is controversial. Moreover, limited clinical studies have evaluated this relationship.Aim: To assess the effects of colchicine, allopurinol and benzbromarone on the risk of cataract in patients with gout.Design: Population-based nested case-control study.Methods: We enrolled 7900 patients who had received a new diagnosis of cataract >3years after gout diagnosis into the study group and 33 475 patients who did not receive a diagnosis of cataract into the control group by matching for age, sex and the year of gout diagnosis at a ratio of 1:1. We used World Health Organization's defined daily dose (DDD) as a measure to assess the dosage of colchicine, allopurinol and benzbromarone exposure. Logistic regression was used to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of cataract.Results: The risk of cataract significantly increased in patients who received colchicine at a cumulative DDD of >= 66.5 (OR=1.17, 95% CI=1.01-1.36, P=0.041). In the age-stratified analysis, patients with gout aged >60 years had a higher risk of cataract (OR=1.27, 95% CI=1.06-1.53, P=0.011) than did patients aged 60 years who received colchicine at a cumulative DDD of >66.5.